Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Autoimmune connective tissue diseases in the COVID-19 pandemic

Lyubomir Dourmishev, MD, PhD*, Dimitrina Guleva, MD, Joana Pozharashka, MD, Kossara Drenovska, MD, PhD, Lyubka Miteva, MD, PhD, Snejina Vassileva, MD, PhD

Department of Dermatology and Venereology, Medical University, Sofia, Bulgaria

Abstract Autoimmune connective tissue diseases are a heterogeneous group of clinical entities sharing a common feature—an impairment of structural components like collagen and elastin, arising by autoimmune mechanisms. Because most patients are on a long-term immunosuppressive therapy, which renders them vulnerable to infections, a new challenge appears in front of physicians in the coronavirus disease 2019 (COVID-19) era. Immune mechanisms are substantial for the control and ceasing of viral infections, and their impairment may cause serious complications; however, data from immunosuppressed transplant patients do not reveal a higher frequency or diseases’ severity in those infected by COVID-19. Several immunotherapies used to treat autoimmune connective tissue diseases favorably modulate the immune response of severe acute respiratory syndrome coronavirus (SARS-CoV-2)–infected patients. The present review highlights the problems of susceptibility, severity, and therapeutic options in patients with autoimmune connective tissue diseases during the COVID-19 pandemic. The relationship between autoimmune connective tissue diseases and COVID-19 infection is explained with antiviral protection genes expression, hypercytokinemia, and lymphohistiocytosis/macrophage activation mechanisms. Recommendations concerning therapy for prevention during the pandemic period or in case of concomitant COVID-19 infection are also presented. Clinical trials are ongoing regarding COVID-19 therapy blocking the cytokine response. © 2021 Elsevier Inc. All rights reserved. © 2020 Elsevier Inc. All rights reserved.

Introduction

Autoimmune connective tissue disorders (ACTDs) are a heterogeneous group of diseases and syndromes characterized by a single feature—an impairment of structures like collagen and elastin, arising by autoimmune mechanisms. This damage determines an involvement of both skin and internal organs. Due to their specific clinical characteristics, the potential biomarkers of the diseases’ severity and progression are various autoantibodies and other soluble mediators. Because most patients with ACTDs are on long-term immunosuppressive therapy, which renders them vulnerable to infections, a new challenge confronts dermatologists treating them at the time of the COVID-19 pandemic.

SARS-CoV-2 virus, the agent of COVID-19 infection, belongs to Coronaviridae, a family of single-stranded RNA viruses affecting many animals; however, six other coronaviruses are also known to infect humans. More than 17 million COVID-19 cases were reported worldwide by the World Health Organization (WHO) by the end of July 2020, subsequently causing more than 660,000 deaths. The infection has been proclaimed a pandemic only for a comparatively few months.

COVID-19 infection has an incubation period of 2 to 14 days and begins with fever, fatigue, and upper and lower respiratory tract signs and symptoms, mimicking those in acute lupus erythematosus (LE). Some individuals might be asymptomatic, but they are contagious and can transmit the...
infection. The immune mechanisms are substantial for the control of viral infections, and their impairment may cause serious complications. Several immunotherapies may modulate the immune response of SARS-CoV-2–infected patients. Efforts should also be directed toward more precise titration of immunosuppressive drugs to avoid relapses and at the same time prevent a possible COVID-19 infection.

**Lupus erythematosus**

The pathophysiology of LE is related to defects in the DNA methylation of various cells, especially in T cells, and overexpression of defective methylated genes such as ACE2 (angiotensin-converting enzyme 2). This makes patients sensitive to oxidative stress and relapses caused by some environmental factors. Epigenetic dysregulation of ACE2 and interferon-regulated genes has been suggested to aggravate SARS-CoV-2 sensitivity in patients with lupus and to lead to new flares. The relationship between these two diseases is explained by the pathogenesis of COVID-19, which is based on the expression of interferon genes responsible for the antiviral protection. The activation of these genes may lead to hypercytokinemia, also known as a "cytokine storm." Some authors suggest that COVID-19 induces muted responses without interferon induction and results in a fulminant reaction to infections. The cytokine storm leads to secondary hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS), which often can be triggered by infections. LE may be associated with an increased risk of HLH/MAS. Some have speculated that patients with lupus might be at an increased risk of a cytokine storm during SARS-CoV-2 infection, whereas others have suggested that the genetically determined endogenous elevations of interferon-α could have protective and therapeutic roles.

As an autoimmune disease with immune dysregulation, skin and/or internal organ damage, and potential comorbidities, LE places the patient at risk. In these unpredictable times with a pandemic of a novel virus, many questions arise about patients at risk, especially the elderly and those with comorbidities (diabetes, cardiovascular, pulmonary, or oncologic diseases) and concomitant medications. Not enough information about the association of autoimmune disorders and COVID-19 is available in the literature; however, a recent study suggests a relatively low rate in patients with systemic LE (SLE), proposing as a possible explanation the common use of antimalarials. Some signs and symptoms of the COVID-19 infection may mimic those of SLE. For instance, fatigue is a common symptom of both COVID-19 and lupus, as well as some skin manifestations. Also, in patients with SLE who suffer from fatigue, a SARS-CoV-2 infection could aggravate these complaints. A recent report of an autopsy presents the main features of COVID-19 infections: diffuse alveolar damage, interstitial mononuclear/lymphocytic infiltrates, and hyaline membrane formation. In SLE, lymhopenia is a common disease activity criterion and is also associated with increased disease severity and mortality.

The skin manifestations of COVID-19 are rare but are also included in the list of findings. LE presents with a wide range of lesions that indicate disease activity or disease control (Figure 1). On this basis, skin lesions could be easily confused. An association of COVID-19 and high levels of lupus anticoagulant has been reported in 31 out of 35 patients with prolonged activated partial thromboplastin time. Lupus anticoagulant is known to increase the risk of thrombosis in SLE or
antiphospholipid syndrome; it could be a marker representing the risk of thrombosis in patients with COVID-19, and anticoagulant administration is recommended. The levels of ferritin and C-reactive protein may be used as early detectors for a developing cytokine storm in the course of COVID-19 infection.

A patient with SLE was admitted to the emergency unit due to exertional dyspnea, thoracic pain, and cough. A false-positive SARS-CoV-2 serologic test was reported. The authors suggested that in patients with SLE the serologic tests have to be evaluated with caution due to possible nonspecific cross-reaction to various autoantibodies, as was reported for human cytomegalovirus.

An Italian working group reported on their experience with patients with SLE and cutaneous LE. Cutaneous lesions have been stable in all patients. Most of them have been treated with hydroxychloroquine (HCQ) in combination with corticosteroids (CSs), azathioprine, thalidomide, or methotrexate (MTX). Those receiving systemic CS therapy have received the prednisone equivalent of less than 20 mg/daily. Some of the patients experienced mild to moderate COVID-19 findings. None of the patients has shown a relapse of the underlying disease. Contrary to the Italian group, independent reports from Michigan and France described patients with SLE who tested positive for COVID-19 infection, all of them in a clinical remission of the underlying disease and under long-term HCQ exposure. Most of them required intensive care with ventilation, and a few patients died. SLE patients may develop more severe complications from the new virus than patients without autoimmune disease.

Many LE patients are treated with immunosuppressive agents to control relapses and to prevent complications. The exact role of the virus in the pathogenesis of lupus and the aggravation of the signs and symptoms caused by the infection is unclear.

Medications, especially CSs and biologics, can increase the risk of infections. Recommendations for therapy are shown in Table 1. Many trials are ongoing regarding COVID-19 therapy to block the cytokine response with anakinra and tocilizumab (a ClinicalTrials.gov search on January 4, 2021 showed 14 and 39 active or completed trials, respectively).

CSs have antinflammatory and immunomodulatory effects, but their use to suppress the cytokine storm is not recommended; however, they can reduce the hyperinflammation due to sepsis and decrease the mortality rate. If patients should not discontinue their steroid medication, then the daily dose should be reduced to 10 mg/day or less prednisone equivalent. Opinions concerning MTX are contradictory, but some authors propose its discontinuation. Cyclophosphamide is a cytotoxic and immunosuppressive drug, which makes it inappropriate to start or to continue the

| Autoimmune connective tissue disease | Preventive measures during the pandemic period | If positive for COVID-19 |
|--------------------------------------|-----------------------------------------------|-------------------------|
| Lupus erythematosus                  | Reduce the dose of the CS. Discontinue MTX or reduce the dose to <10 mg/day if possible. | In newly diagnosed LE, start with HCQ. In severe cases, discontinue or reduce the dose of the CS or biologics. Alternatively, switch to HCQ. |
| Dermatomyositis                      | Low doses of CS or azathioprine, MTX, IVIG, mycophenolate mofetil, cyclosporine, and cyclophosphamide can be used in patients who are unresponsive to CS. | Use the lowest possible dose of CS and a second agent to be included, excluding MTX, If not responsive to CS, switch to IVIG, anakinra, cyclosporine, or adalimumab. |
| Scleroderma                          | Avoid systemic CS, MTX. In severe cases of pansclerotic morphea, MTX or CSs should be reduced to the lowest effective dose. | Discontinue biologics if possible. |
| Vasculitits                          | Nonsteroidal antiinflammatory drugs, dapsone, colchicine, and low-dose systemic CS can be tried in mild cases during the pandemic period. In severe or resistant cases, low doses of MTX, IVIG, and tocilizumab can be used. | |

ACTD, autoimmune connective tissue disorders; CS, corticosteroid; HCQ, hydroxychloroquine; LE, lupus erythematosus; IVIG, intravenous immunoglobulin; MTX, methotrexate.
therapy during the pandemic. Immunomodulators such as intravenous immunoglobulins (IVIGs) are currently used more often as an alternative in autoimmune diseases therapy, particularly for resistant cases.\textsuperscript{30} No data are available on the interaction between COVID-19 infection and IVIG therapy. Regarding the mode of action and the administration of the drug, it is not contraindicated nor is there a need for it to be discontinued.

Antimalarial drugs are among the most commonly used therapies in cutaneous LE. They are probably the most suitable medication during the pandemic due to their protective antiviral and anti-inflammatory effect. They may reduce lipid levels, as well as the risk of thrombosis, and may control the blood sugar in lupus patients.\textsuperscript{31-34} Chinese authors have established that these drugs relieve respiratory findings and improve the radiologic presentations, as well as the duration of the disease.\textsuperscript{35,36} Some independent clinical studies, \textit{in vivo} or \textit{in vitro}, have been performed concerning the positive effect of antimalarial drugs in COVID-19 infection.\textsuperscript{37,39} The US Food and Drug Administration has approved the drug for off-label use in some cases of COVID-19.\textsuperscript{40} Concerning the prophylaxis of the medical professionals working with COVID-19, patient recommendations are in dispute. For example, the Indian Council of Medical Research has recommended it, whereas physicians at Johns Hopkins University Hospital in Baltimore, Maryland do not advise it.\textsuperscript{41,42}

Dermatomyositis

Dermatomyositis (DM) is a rare ACTD belonging to the group of idiopathic inflammatory myopathies. DM affects the skin and skeletal muscles, presenting with a typical cutaneous eruption (e.g., heliotrope erythema, Gottron papules) and proximal muscle weakness. A variety of other organs and systems may be involved, such as the lungs, joints, gastrointestinal tract, and heart.

Although a few publications have suggested that patients with autoimmune disorders and immunosuppression do not appear to be more severely infected by COVID-19, data are limited. There are no large reports about the frequency of infection or the risk of severe COVID-19 in patients with ACTD involving the skin, namely LE, DM, and systemic sclerosis. Although there are a few case series available for patients with SLE and COVID-19 infection, there are none for DM, possibly due to the low incidence of the disease.\textsuperscript{25}

Three immunogenic linear epitopes with high sequence identity to SARS-CoV-2 proteins have been reported in patients with DM, suggesting that latent exposure to the Coronaviridae family might contribute to musculoskeletal autoimmune disease development.\textsuperscript{43} Myositis has been described in a patient with COVID-19. Although an autoimmune myositis was suspected, there was a lack of autoantibodies to confirm the diagnosis.\textsuperscript{44}

In our opinion, in the context of the current COVID-19 pandemic, DM patients should be considered at greater risk for severe complicated SARS-CoV-2 infection.\textsuperscript{45} The latter is not merely related to their immunocompromised state.

SARS-CoV-2 virus causes an influenza-like pulmonary illness, transmissible mainly through respiratory route. Patients suffering from an underlying lung disease, and especially those on chronic immunosuppression, are at higher risk of infection with SARS-CoV-2. This is the case for DM patients with interstitial lung disease (ILD). ILD is a common clinical feature in ACTD. Most patients with ILD, in the context of ACTD, experience a chronic benign course and have a relatively favorable prognosis; however, patients with DM or polymyositis tend to have more acute progression of ILD.\textsuperscript{46}

Another factor, with a potentially fatal impact on DM patients, is the extent of muscle involvement. In severe DM cases, weakness of intercostal muscles may lead to breathing impairment and acute respiratory distress syndrome.\textsuperscript{47} The risk is even greater if a viral infection occurs and exacerbates the disease course.

DM is considered a paraneoplastic phenomenon because in 24% of adult cases an underlying malignancy is present.\textsuperscript{48} Considering that cancer patients are more at risk for infection than healthy individuals, the possibility of cancer-associated myositis should be actively excluded in every adult patient with DM, especially during the current COVID-19 epidemic. A recent cross-sectional study from China, encompassing a total of 1524 patients with cancer, suggested that cancer patients have a twofold increased risk of COVID-19 infection compared with the general population and are more likely to have higher morbidity and mortality.\textsuperscript{49} According to another study, cancer patients infected with COVID-19 are at 3.5 times higher risk of requiring mechanical ventilation compared with the general population.\textsuperscript{50}

Emerging data show that venous thromboembolism (VTE) occurs in approximately 20% of patients infected with COVID-19. This complication was reported predominantly in severely ill patients and was related to poor outcome. The risk of VTE remained high despite the use of guideline-recommended thromboprophylaxis.\textsuperscript{51} Epidemiologic studies have revealed an elevated risk of VTE, including pulmonary embolism and deep venous thrombosis, in adults with idiopathic inflammatory myopathies.\textsuperscript{52} In additions, recent data emphasized the different frequency of VTE in DM and polymyositis, respectively.\textsuperscript{53,54} DM patients show an eight times higher risk of VTE compared with the general population, and in polymyositis the risk is six times higher.\textsuperscript{54} Increased VTE risk may also exist in clinically amyopathic DM.\textsuperscript{55}

Along with the gradually increasing understanding of COVID-19 pathophysiology, several drugs commonly used in rheumatology to treat autoimmune diseases have emerged as potential COVID-19 medications. In patients with DM, HCQ is routinely prescribed by dermatologists due to its beneficial effect on the skin lesions.\textsuperscript{56} Studies from China indicate that immunomodulatory therapies like tocilizumab and baricitinib might possess the
potential to attenuate the cytokine storm that causes terminal organ damage, multiorgan failure, and fatal outcomes in patients with severe COVID-19 pneumonia.\textsuperscript{37}

Tocilizumab, a humanized monoclonal antibody against the IL-6 receptor, is among the four biologic therapies to consider for refractory juvenile DM treatment when indicated.\textsuperscript{58} The presumed effect of tocilizumab in patients with severe COVID-19 is explained by the central role of IL-6 in the pathogenesis of cytokine release syndrome. A retrospective study with 21 patients severely affected by COVID-19 revealed that tocilizumab treatment improved the clinical manifestations in the majority of cases.\textsuperscript{39}

Janus kinase inhibitor baricitinib might reduce the ability of the SARS-CoV-2 virus to infect the lung cells by inhibiting the regulator of endocytosis AP2-associated protein kinase 1 and is worth being trialed.\textsuperscript{60} A patient with juvenile DM, refractory to wide array of antiinflammatory therapies, was described as having as having a good response to baricitinib.\textsuperscript{61} Similar cases with improvement in adult DM patients have been reported after therapy with another Janus kinase inhibitor, ruxolitinib.

Systemic sclerosis

Systemic sclerosis (SSc) (scleroderma) is a chronic autoimmune connective tissue disease with distinctive pathognomonic features, comprising vascular derangement, immune system activation, tissue fibrosis, and a heterogeneous clinical profile. SSc is clinically characterized by Raynaud phenomenon, sclerodactyly, fibrosis, and dystrophic skin lesions associated with internal organ involvement. Localized scleroderma is limited to the skin and underlying tissues.\textsuperscript{62} As with other ACTD, it is expected that patients with SSc may have a higher infection risk for COVID-19 than the general population due to the autoimmune dysregulation and chronic immunosuppressant therapies.\textsuperscript{63} It is still unclear to what extent SSc patients are susceptible to SARS-CoV-2 or how severe the association of these diseases may be, as revealed in the available single case reports or small series. A SSc patient who developed very mild COVID-19 disease was successfully treated with intravenous tocilizumab.\textsuperscript{64} Disease in three patients with severe bilateral interstitial pneumonia and sudden respiratory failure was controlled with rituximab and in one case tocilizumab.\textsuperscript{65}

ILD is found in up to 80\% of SSc patients and is one of the most severe complications.\textsuperscript{66} Such patients are much more at risk to develop a severe COVID-19 lung infection.\textsuperscript{67} In addition, COVID-19 may overlap with and even aggravate ILD in SSc, making the early phase of infection indistinguishable from ILD disease progression.

Systemic steroids and MTX are preferred therapeutic options. HCQ is seldom used in SSc; however, its antiviral properties have produced promising results.\textsuperscript{73} Tocilizumab intravenously led to clinical and radiologic improvement for patients with ILD who were SARS-CoV-2 positive.\textsuperscript{64}

Vasculitis

Cutaneous vasculitis is a large group of disorders that may progress to organ involvement.\textsuperscript{74} Therapy depends on the diameter of the affected vessels, the density of the lesions, and the presence of organ damage. In addition, cytotoxic treatment of vasculitis usually raises the risk of infections. The diagnostic problem is that COVID-19 patients may also have cutaneous eruptions resembling vasculitis or vasculopathy.\textsuperscript{75,76} Petechial and transient livedo reticularis–like (Figure 2) eruptions have been described.\textsuperscript{77} A report from Wuhan, China revealed that patients with COVID-19 pneumonia developed cyanosis of their fingers, bullae, and cutaneous necrosis (Figure 3).\textsuperscript{78} One patient developed Schamberg’s purpura.\textsuperscript{79} A patient with proteinase 3-antineutrophil cytoplasmic antibody granulomatosis with polyangiitis on CS and rituximab who developed severe COVID-19 pneumonia was successfully treated with antivirals and HCQ.\textsuperscript{80}

Fig. 2 Livedo reticularis–like eruption is commonly seen in systemic lupus erythematosus, but it is a cutaneous manifestation of COVID-19 as well.

Fig. 3 Cutaneous necrosis is noted in severe systemic lupus erythematosus, dermatomyositis, and vasculitis, as well as in vasculopathies and COVID-19 infection.
Antineutrophil cytoplasmic antibody–positive polyangiitis treated with rituximab suggests that B-cell depletory therapy may not be a risk factor for severe forms and may even favor a milder course of COVID-19 disease.81

No data about precautions are currently available concerning therapy and prevention of new flares of ACTD. The Italian Society of Dermatologists recommends the following for patients:82

- Maintain social distancing, avoiding public transportation, public spaces; if necessary, stay at least 2 meters (6 feet) away from other people.
- Use face coverings.
- Observe some hygiene rules—washing the hands regularly with soap and warm water and using an alcohol-based hand sanitizer with at least 60% alcohol.
- Conduct regular follow-up visits by phone.
- Do not interrupt ongoing therapy.
- Inform your physician if in case of COVID-19 symptoms or new flares.

If signs and symptoms of COVID-19 infection occur, a period of self-isolation at home can help to reduce the transmission. If shortness of breath occurs, patients should contact their physicians.

Conclusions

Physicians should encourage ACTD patients to continue their maintenance therapies. In turn, ACTD patients may prevent infection by avoiding social contacts. In case of infections, we recommend discontinuation of immunosuppression. Larger observational studies are needed to establish the risk in patients with autoimmune diseases and to provide appropriate therapeutic guidelines.

References

1. Abdel Razek AA. Imaging of connective tissue diseases of the head and neck. Neuroradiol J. 2016;29:222–230.
2. Jog NR, James JA. Biomarkers in connective tissue diseases. J Allergy Clin Immunol. 2017;140:1473–1483.
3. Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020. doi:10.1038/s41586-020-2550-z.
4. WHO Situation report—193. Coronavirus disease 2019 (COVID-19). WHO; 2020 Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200731-covid-19-sitrep-193.pdf?sfvrsn=42a0221d_4. Accessed January 5, 2021.
5. Centers for Disease Control and Prevention. Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19). 2020. CDC; Dec 8, 2020 Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html#. Accessed on January 5, 2021.
6. Teruel M, Sawalha AH. Epigenetic variability in systemic lupus erythematosus: what we learned from genome-wide DNA methylation studies. Curr Rheumatol Rep. 2017;19:32.
7. Sawalha AH, Zhao M, Coit P, Lu Q. Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients. Clin Immunol. 2020;215.
8. Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2020. doi:10.1002/jmv.26232.
9. Blanco-Melo D, Nilsson-Payant B, Liu W, et al. SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems. Cell. 2020;181:1036–1045.e9.
10. Mehta P, McAuley DF, Brown M, et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–1034.
11. Ramos-Casals M, Brito-Zerón P, López-Guillermo A, et al. Adult haemophagocytic syndrome. Lancet. 2014;383:1503–1516.
12. Crayne CB, Albeituni S, Nichols KE, et al. The immunology of macrophage activation syndrome. Front Immunol. 2019;10:119.
13. Niewold TB. Interferon alpha as a primary pathogenic factor in human lupus. J Interferon Cytokine Res. 2011;31:887–892.
14. Torres T, Puig L. Managing cutaneous immune-mediated diseases during the COVID-19 pandemic. Am J Clin Dermatol. 2020;21:307–311.
15. Rademaker M, Baker C, Foley P, et al. Advice regarding COVID-19 and use of immunomodulators, in patients with severe dermatological diseases. Australas J Dermatol. 2020;61:158–159.
16. Ansarin K, Taghizadeh A, Safri S, et al. COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs. Ann Rheum Dis. 2020 annrheumdis-2020-218737.
17. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–422.
18. Yee AM, Buyon JP, Yip YK. Interferon alpha associated with systemic lupus erythematosus is not intrinsically acid labile. J Exp Med. 1989;169:987–993.
19. Bowles L, Platton S, Yartney N, et al. Lupus anticoagulant and abnormal coagulation tests in patients with COVID-19. N Engl J Med. 2020;383:288–290.
20. Reyes Gil M, Barouqa M, Szymanski J, et al. Assessment of lupus anticoagulant positivity in patients with Coronavirus disease 2019 (COVID-19). JAMA Netw Open. 2020;3.
21. Sawalha AH, Manzi S. Coronavirus disease-2019: implication for the care and management of patients with systemic lupus erythematosus. Eur J Rheumatol. 2020. doi:10.3152/jrheum.200055.
22. Elefante E, Tani C, Zucchi D, et al. Are patients with systemic lupus erythematosus more prone to result false-positive for SARS-CoV2 serology? Clin Exp Rheumatol. 2020;38:577.
23. Vezzoli P, Di Mercurio M, Carugno A, et al. Cutaneous lupus erythematosus patients in a high-epidemic COVID-19 area, Bergamo, Italy. Dermatol Ther. 2020;e13776.
24. Wallace B, Lasher L, Marder W, et al. Patients with lupus with COVID-19: University of Michigan experience. Ann Rheum Dis. 2020 annrheumdis-2021-217794.
25. Mathian A, Mahevas M, Rohmer J, et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis. 2020;79:837–839.
26. Jung JY, Suh CH. Infection in systemic lupus erythematosus, similarities, and differences with lupus flare. Korean J Intern Med. 2017;32:429–438.
27. Annane D, Bellissant E, Bolhaar PE, et al. Corticosteroids for treating sepsis. Cochrane Database Syst Rev. 2015;2015 CD002243.
28. Reynolds SD, Mathur AN, Chiu YE, et al. Systemic immunosuppressive therapy for inflammatory skin diseases in children: expert consensus-based guidance for clinical decision-making during the COVID-19 pandemic. Pediatr Dermatol. 2020;37:424–434.
29. Wang C, Rademaker M, Barker C, et al. COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: an Australian/New Zealand consensus statement. Australas J Dermatol. 2020;61(3):210–216. doi:10.1111/ajd.13131.
30. Dourmishev L, Galeva D, Mitteva L. Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology. Wien Med Wochenschr. 2018;168:213–217.
31. Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus. 1996;5(Suppl 1):S16–S22.
32. Wallace DJ, Metzger AL, Stecher VJ, et al. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med. 1990;89:322–326.
33. Pierangeli SS, Harris EN. In vivo models of thrombosis for the antiphospholipid syndrome. Lupus. 1996;5:451–455.
34. Penn SK, Kao AH, Schott LL, et al. Hydroxychloroquine and glycerina in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol. 2010;37:1136–1142.
35. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14:72–73.
36. Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol. 2020;214.
37. D’Alessandro S, Scaccabarozzi D, Signorini L, et al. The use of antimalarial drugs against viral infection. Microorganisms. 2020;8:35.
38. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71:732–739.
39. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.
40. Owens B. Excitement around hydroxychloroquine for treating COVID-19 causes challenges for rheumatology. Lancet Rheumatol. 2020;2:e257.
41. Indian Council of Medical Research. Advisory on the use of hydroxychloroquine as prophylaxis for SARS-CoV2 infection. MoHFW; 2020. Available at: https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf. Accessed January 5, 2021.
42. Writing Group of the Johns Hopkins University and Johns Hopkins Hospital COVID-19 Treatment Guidance Working Group. JHMI Clinical Guidance for Available Pharmacologic Therapies for COVID-19. Available at: https://www.hopkinsguides.com/hopkins/sub?cmd=review&displaytype=789;1128&name=5_53874_PDF.
43. Megremis S, Walker TDJ, He X, et al. Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis. Ann Rheum Dis. 2020;79(10):1383–1386. doi:10.1136/annrheumdis-2020-217522.
44. Beydon M, Chevalier K, Al Tabaa O, et al. Myositis as a manifestation of SARS-CoV-2. Ann Rheum Dis. 2020. In press. doi:10.1136/annrheumdis-2020-217573.
45. Wang Y, Du G, Zhang G, et al. Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge for the future. Ann Rheum Dis. 2020. Annrheumdis-2020-218594. doi:10.1136/annrheumdis-2020-218594.
46. Won Huh J, Soon Kim D, Keun Lee C, et al. Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respir Med. 2007;101:1761–1769.
47. Selva-O’Callaghan A, Sanchez-Stijes L, Muñoz-Gall X, et al. Respiratory failure due to muscle weakness in inflammatory myopathies: maintenance therapy with home mechanical ventilation. Rheumatology (Oxford). 2000;39:914–916.
48. Zahir ZA, Baer AN. Malignancy in myositis. Curr Rheumatol Rep. 2011;13:208–215.
49. Yu J, Ouyang W, Chua MLK, et al. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol. 2020;6:1108–1110.
50. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–337.
51. Al-Ani F, Chehade S, Lazo-Langner A. Thrombosis risk associated with COVID-19 infection. A scoping review. Thromb Res. 2020;192:152–160.
52. Diederichsen LP. Cardiovascular involvement in myositis. Curr Opin Rheumatol. 2017;29:598–603.
53. Li Y, Wang P, Li L, et al. Increased risk of venous thromboembolism associated with polymyositis and dermatomyositis: a meta-analysis. Ther Clin Risk Manag. 2018;14:157–165.
54. Curruthers EC, Choi HK, Sayre EC, et al. Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study. Ann Rheum Dis. 2016;75:110–116.
55. Kirchhof MG, Dutz JP. Amyopathic dermatomyositis-related thombophilia. JAMA Dermatol. 2015;151:559–561.
56. Danza A, Graña D, Gotí M, et al. Hidroxicloroquina en el tratamiento de las enfermedades autoinmunes sistémicas [Hydroxychloroquine for autoimmune diseases. Rev Med Chil. 2016;144:232–240.
57. Askanae AD, Khalili L, Buyon JP. Thoughts on COVID-19 and autoimmune diseases. Lupus Sci Med. 2020;7:e000396.
58. Spencer CH, Rouster-Stevens K, Gwenaë H, et al. Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America. Pediatr Rheumatol Online J. 2017;15:50.
59. Xu H, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117:10970–10975.
60. Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395 e30-e31.
61. Papadopoulos C, Hong Y, Omoyminn E, et al. Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. Brain. 2019;142:e8.
62. Careta MF, Romiti R. Localized scleroderma: clinical spectrum and therapeutic update. An Bras Dermatol. 2015;90:62–73.
63. Orlandi M, Lepri G, Bruni C, et al. The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress. Clin Rheumatol. 2020;39:2043–2047.
64. Mihai C, Dobrota R, Schröder M, et al. COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSC-ILD. Ann Rheum Dis. 2020;79:668–669.
65. Avoua O, Airó P, Carlier N, et al. Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab. Ann Rheum Dis. 2020 annrheumdis-2020-217864. doi:10.1136/annrheumdis-2020-217864.
66. Denton CP, Hughes M, Gak N, et al. BSR and BHPR guidance line for the treatment of systemic sclerosis. Rheumatology (Oxford). 2016;55:1906–1910.
67. CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with Coronavirus disease 2019—United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:382–386.
68. Littlejohn E. Keeping lupus patients on hydroxychloroquine during the COVID-19 pandemic. Cleve Clin J Med. 2020;ccc023. doi:10.3949/ccjm.87a.ccc023.
69. Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve. 2015;51:638–656.
70. Karadag A, Kayiran M, Lotti T, et al. Immunosuppressive and immunomodulator therapy for rare or uncommon skin disorders in pandemic years. Dermatol Therapy. 2020;2020:e13686.
71. Dasegh B, Kornreich D, McGuinn K, et al. Colchicine: an ancient drug with novel applications. Br J Dermatol. 2018;178:350–356.
72. Pastuszczak M, Celinska-Löwenhoff M, Sulowicz J, et al. Clinical study on single-organ cutaneous small vessels vasculitis (SoCSVV). Medicine. 2017;96:e6376.
Autoimmune connective tissue diseases in the COVID-19 pandemic

73. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Viral J. 2020;2:69.
74. Shavit E, Alavi A, Sibbald RG. Vasculitis—what do we have to know? A review of literature. Int J Low Extrem Wounds. 2018;17:218–226.
75. Almutairi N, Schwartz RA. COVID-19 with dermatologic manifestations and implications: an unfolding conundrum. Dermatol Ther. 2020:e13544.
76. Five common skin manifestations of COVID-19 identified. Br J Dermatol. 2020;183:e16.
77. Su CJ, Lee CH. Viral exanthem in COVID-19, a clinical enigma with biological significance. J Eur Acad Dermatol Venereol. 2020;34 e251-e252.
78. Zhang Y, Cao W, Xiao M, et al. Clinical and coagulation characteristics of 7 patients with critical COVID-19 pneumonia and acro-ischemia. Zhonghua Xue Ye Xue Za Zhi. 2020;28 41:E006.
79. Wollina U. Schamberg-like purpuric eruptions and tonsillitis in mild COVID-19. Dermatol Ther. 2020:e13766.
80. Guilpain P, Le Bihan C, Foulongne Y, et al. Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia. Ann Rheum Dis. 2020 arnrheumdis-2020-217549.
81. Suárez-Díaz S, Morán-Castaño C, Coto-Hernández R, et al. Mild COVID-19 in ANCA-associated vasculitis treated with rituximab. Ann Rheum Dis. 2020 arnrheumdis-2020-218246.
82. Società Italiana di Dermatologia medica, chirurgica, estetica e delle Malattie Sexualmente Trasmesse (SIDeMaST). Infezione da Coronavirus, Vademecum per i pazienti affetti da malattie bollosi e malattie autoimmuni. SIDeMaST; 2020. Available at: https://www.sidemast.org/blog/infezione-da-coronavirus-vademecum-per-i-pazienti-affetti-da-malattie-bollosi-e-malattie-auto-immuni/. Accessed January 4, 2021.